Navigation Links
Fate Therapeutics Closes $30 Million Series B Financing
Date:11/16/2009

atment options."

Fate Therapeutics is developing its lead Stem Cell Modulator, FT1050, to enhance hematopoietic stem cell (HSC) proliferation and homing. The small molecule is currently undergoing clinical testing at the Dana Farber Cancer Institute and Massachusetts General Hospital in adult patients with hematologic malignancies, such as leukemia and lymphoma, who have undergone nonmyeloablative conditioning therapy and are in need of HSC support. The Phase 1b study is intended to determine the safety and tolerability of introducing FT1050 during the standard course of dual umbilical cord blood transplant and will also track HSC engraftment efficiencies and patient outcomes.

The Company's discovery engine utilizes the most advanced reprogramming technologies for generating cell types of interest to elucidate disease biology and identify targets for therapeutic intervention. Fate Therapeutics' protein-based reprogramming platform in combination with its novel small molecule conditions offers a highly efficient, non-viral, non-DNA based method to recapitulate human physiology for commercial scale drug discovery and therapeutic use. The Company has exclusively in-licensed from The Scripps Research Institute and the Whitehead Institute for Biomedical Research an intellectual property portfolio related to induced pluripotent stem cell (iPSC) technology, including filings that date back to November 2003. This portfolio includes the latest techniques published by Dr. Sheng Ding in October 2009, which use three small molecules to generate iPSCs in a manner that is 200 times more efficient than and twice as fast as conventional methods for reprogramming adult human cells.

"The Company is well-positioned to aggressively advance its leading iPSC technology platform for use in its own internal discovery programs as well as with strategic partners," said Scott Wolchko, chief financial officer of Fate Therapeutics. "With this Series B fina
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference
2. Esperion Therapeutics Initiates Phase I Clinical Study for ETC-1002
3. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
4. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
5. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
6. Nektar Therapeutics Reports Third Quarter 2009 Financial Results
7. Tolera Therapeutics Files IND Application for TOL101, Appoints OToole to Lead Clinical Operations
8. Amicus Therapeutics Announces Third Quarter 2009 Financial Results and Strategic Business Updates
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Cornerstone Therapeutics to Host Third Quarter 2009 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2014)... , November 27, 2014 ... revolutionising the management of tooth decay, today announces ... of its Calcivis® Caries Activity Imaging System. ... a sophisticated medical device and consumable combination designed ... caries (tooth decay). It involves a unique, proprietary ...
(Date:11/26/2014)... NOVEMBER 21, 2014 (PRWEB) November 26, 2014 ... health-oriented communications network, today announced the organization has won ... Rx Club Awards. Digitas Health LifeBrands was honored with ... four other PHCG agencies received eight Awards of Excellence. ... creative aspects of pharmaceutical advertising and promotion. The Awards ...
(Date:11/26/2014)... Texas (PRWEB) November 26, 2014 ... Industryā€¯ is a professional and in-depth research report ... Bifluoride information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
(Date:11/26/2014)... In keeping with the holiday spirit, ... last-minute Thanksgiving savings. The company is offering up a ... lines this holiday weekend as well as a photo ... Cyber Monday are right around the corner, and DNA ... customers and those looking to explore their ancestry, health, ...
Breaking Biology Technology:Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 2Calcivis Completes Clinical Study of Novel Caries Activity Imaging System 3Publicis Healthcare Wins 20 Rx Club Awards 2Publicis Healthcare Wins 20 Rx Club Awards 3Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3DNA Spectrum Offers Last Minute Thanksgiving Coupons 2DNA Spectrum Offers Last Minute Thanksgiving Coupons 3
... 11 Telik, Inc.,(Nasdaq: TELK ) reported a net ... quarter ended June 30, 2008, compared with a net loss ... in 2007. The,$13.6 million net loss for the second quarter ... to auction rate securities, which,is reflected in interest and other ...
... Inc., administrator for the,HealthShares(TM) Indexes, a series of ... today announced the following,change effective on the opening ... (Frankfurt, Germany: BIO) will replace Speedel Holding AG ... Speedel,Holding AG is being acquired by Novartis AG ...
... Aug. 11 Informed Medical Communications,(IMC), a leading ... issued its position today on recent revisions,to the ... with the,PhRMA Code," noted Dr. Jaime Nguyen, Medical ... we have continually monitored,the compliance trends so that ...
Cached Biology Technology:Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index 2Informed Medical Communications Highlights Opportunity in Revised PhRMA Code 2
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
(Date:11/11/2014)... 2014  Forensicon, Inc., a Chicago ... announce the promotion of Yaniv Schiff from ... In Schiff,s new role as Director, he will lead ... forensics examiners and provide leadership within the company,s digital ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon in ...
(Date:11/6/2014)... Fla. -- A groundbreaking paper from a team of ... understanding of how plants could adapt to and survive ... research, published in the latest issue of the journal ... chromatin (the complex of DNA and proteins) is organized ... so that some genes are turned on and others ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2Maize analysis yields whole new world of genetic science 2
... S. Serianni is providing new insights that could have ... points out that biological compounds known as dicarbonyl sugars ... breakdown of the simple sugar, glucose. The formation of ... concentrations in the blood and plasma of diabetics are ...
... Dec. 12, 2012 Wake Forest Baptist Medical Center ... its academic and clinical research and discoveries into marketable ... enterprise, Wake Forest Innovations, is being led by Chief ... who is also President of the Piedmont Triad ...
... humans and 200 Asian elephants every year. One of the ... elephants into ranges away from humans, often into national parks. ... elephants raiding crops, breaking into homes and injuring or killing ... published Dec. 7 in PLOS ONE by the ...
Cached Biology News:Notre Dame research may have important implications for combating diabetes 2Wake Forest Baptist Medical Center Launches Wake Forest Innovations 2Wake Forest Baptist Medical Center Launches Wake Forest Innovations 3Relocating elephants fails to decrease human-wildlife conflict 2
Concentration: 1mg/ml. Antigen: Propidium Iodide ...
Apoptosis Detection Systems and Reagents...
...
DAPI: 4', 6-Diamino-2-phenylindole dihydrochloride. Antifade Solution: p-Phenylenediamine and glycerol in PBS solution. 0.4g/mL DAPI suspended in Antifade....
Biology Products: